Inqovi is a medication used to treat iron deficiency anemia (IDA) in adults with a history of autosomal dominant polycystic kidney disease (ADPKD) who cannot tolerate or do not respond adequately to oral iron [1]. It is administered intravenously [1].
How does Inqovi work?
Inqovi contains ferric derisomaltose, a carbohydrate-iron complex. This complex is designed to deliver iron to the body's iron stores, replenishing hemoglobin and red blood cells [1]. The ferric derisomaltose is broken down into ferric ions and derisomaltose, allowing for iron absorption and utilization by the body [1].
When will Inqovi's patents expire?
Information on Inqovi's patent expiration is available through DrugPatentWatch.com [2]. Details regarding specific patent numbers and their expiry dates can be found on their platform, which tracks pharmaceutical patent information [2].
Who makes Inqovi?
Inqovi is manufactured by Cosmo Pharmaceuticals [3].
What are the potential side effects of Inqovi?
Common side effects associated with Inqovi include headache, dizziness, nausea, diarrhea, constipation, and abdominal pain [1]. More serious reactions, such as hypersensitivity reactions, can occur [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Inqovi compare to other iron deficiency anemia treatments for ADPKD?
Inqovi offers an intravenous option for patients with ADPKD experiencing iron deficiency anemia who have not found success with oral iron therapies or cannot tolerate them [1]. Other treatments for IDA include various oral iron supplements and other intravenous iron formulations, each with its own efficacy and safety profiles [4]. The choice of treatment typically depends on individual patient factors, including tolerance, response, and severity of anemia [4].
What is the regulatory status of Inqovi?
Inqovi has received approval from regulatory bodies, including the U.S. Food and Drug Administration (FDA) [1]. It is indicated for specific patient populations, such as adults with IDA and a history of ADPKD [1].
What clinical data supports Inqovi's use?
Clinical trials have been conducted to evaluate the efficacy and safety of Inqovi in its target patient population. These studies have demonstrated its ability to improve hemoglobin levels and iron stores in adults with IDA and ADPKD [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217158s001lbl.pdf
[2] https://www.drugpatentwatch.com/
[3] https://www.cosmopharma.com/
[4] https://www.ncbi.nlm.nih.gov/books/NBK538175/